(Q87429646)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26961066%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Heart failure: SGLT2 inhibitors and heart failure -- clinical implications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26961066%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

Itamar Raz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26961066%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Avivit Cahn

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26961066%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

10 March 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26961066%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Cardiology

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26961066%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26961066%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26961066%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

185-186

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26961066%20AND%20SRC:MED&resulttype=core&format=json

Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.35

Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.35

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.35

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.35

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.35

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.35

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.35

Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.35

Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2016.35

31 March 2020

Identifiers

DOI

10.1038/NRCARDIO.2016.35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26961066%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference